SCHEMBL7127063

SCHEMBL7127063

CC(=O)N1CCc2cc(Nc3ccnc4cc(-c5ccccn5)sc34)ccc21

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.63
HTR2C P28335 1/20 0.44
HTR2B P41595 1/20 0.44
HPGD P15428 1/20 0.44
PLK1 P53350 1/20 0.43
NPC1 O15118 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TRIM24 O15164 2/20 0.41
CYP11B1 P15538 2/20 0.39
CYP11B2 P19099 2/20 0.39
EGFR P00533 1/20 0.39
NOTUM Q6P988 4/20 0.39
JAK2 O60674 1/20 0.39
TYK2 P29597 1/20 0.39
TSHR P16473 1/20 0.38
PDE7A Q13946 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14651256 0.78 SYK (1.00) SYKPLK1EGFRJAK2TYK2
SCHEMBL7126148 0.76 FLT1 (0.43) SYKEGFR
SCHEMBL7125165 0.70 SYK (0.64) SYKEGFR
SCHEMBL7120775 0.69 EGFR (0.60) SYKEGFR
SCHEMBL7126927 0.69 FLT1 (0.73) EGFR
SCHEMBL7129261 0.69 FLT1 (0.48) SYKEGFR
SCHEMBL14651137 0.69 SYK (1.00) SYK
SCHEMBL7117752 0.68 EGFR (0.57) SYKPLK1EGFRJAK2TYK2
SCHEMBL6072495 0.67 SYK (0.57) SYKHPGDPLK1NPC1TP53
SCHEMBL9267504 0.67 SYK (0.54) SYKHTR2CHPGDPLK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2003-08-28 US claimed
US-6492383-B1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2002-12-10 US claimed
EP-1028964-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2000-08-23 EP claimed
WO-1999024440-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 1999-05-20 WO claimed
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2003-08-28 US disclosed
US-6492383-B1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents PFIZER INC. 2002-12-10 US disclosed
EP-1028964-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2000-08-23 EP disclosed
WO-1999024440-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162795-A1 Thienopyrimidine and thienopyridine derivatives useful as anticancer agents TYMP, DPYD, HPRT1 SYK 3886/4885HTR2C 3112/4885HTR2B 3033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.